Viewing Study NCT04416451


Ignite Creation Date: 2025-12-24 @ 11:50 PM
Ignite Modification Date: 2025-12-25 @ 9:44 PM
Study NCT ID: NCT04416451
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-07-02
First Post: 2020-06-02
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma
Sponsor: Memorial Sloan Kettering Cancer Center
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module